Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for PTC Therapeutics, Inc. (PTCT : NSDQ)
 
 • Company Description   
PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

Number of Employees: 939

 
 • Price / Volume Information   
Yesterday's Closing Price: $75.64 Daily Weekly Monthly
20 Day Moving Average: 2,191,174 shares
Shares Outstanding: 80.29 (millions)
Market Capitalization: $6,072.98 (millions)
Beta: 0.47
52 Week High: $87.50
52 Week Low: $35.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.92% -0.41%
12 Week 20.29% 16.85%
Year To Date 67.57% 42.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 WARREN CORPORATE CENTER DRIVE
-
WARREN,NJ 07059
USA		 ph: 908-222-7000
fax: 908-222-7231		 ecavaleri@ptcbio.com http://www.ptcbio.com
 
 • General Corporate Information   
Officers
Matthew B. Klein - Chief Executive Officer and Director
Pierre Gravier - Chief Financial Officer
Michael Schmertzler - Director
Allan Jacobson - Director
Stephanie S. Okey - Director

Peer Information
PTC Therapeutics, Inc. (CORR.)
PTC Therapeutics, Inc. (RSPI)
PTC Therapeutics, Inc. (CGXP)
PTC Therapeutics, Inc. (BGEN)
PTC Therapeutics, Inc. (GTBP)
PTC Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 69366J200
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/26/26
Share - Related Items
Shares Outstanding: 80.29
Most Recent Split Date: (:1)
Beta: 0.47
Market Capitalization: $6,072.98 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.98 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $8.34 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 33.25% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/26/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 9.07
Trailing 12 Months: 8.25
PEG Ratio: 0.27
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 3.41
EPS Growth
vs. Year Ago Period: 114.39%
vs. Previous Quarter: 124.10%
Sales Growth
vs. Year Ago Period: 7.23%
vs. Previous Quarter: 17.96%
ROE
09/30/25 - -194.11
06/30/25 - -106.31
03/31/25 - -78.56
ROA
09/30/25 - 33.15
06/30/25 - 30.61
03/31/25 - 32.11
Current Ratio
09/30/25 - 2.32
06/30/25 - 3.62
03/31/25 - 3.89
Quick Ratio
09/30/25 - 2.26
06/30/25 - 3.57
03/31/25 - 3.85
Operating Margin
09/30/25 - 44.90
06/30/25 - 38.32
03/31/25 - 36.76
Net Margin
09/30/25 - 42.25
06/30/25 - 35.65
03/31/25 - 33.56
Pre-Tax Margin
09/30/25 - 41.65
06/30/25 - 37.74
03/31/25 - 36.74
Book Value
09/30/25 - -1.96
06/30/25 - -2.61
03/31/25 - -2.34
Inventory Turnover
09/30/25 - 1.71
06/30/25 - 1.79
03/31/25 - 1.98
Debt-to-Equity
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Capital
09/30/25 - -
06/30/25 - -
03/31/25 - -
 

Powered by Zacks Investment Research ©